TABLE 1.
Gene | Synonym(s) | Expression level of gene (arbitrary units)a
|
||
---|---|---|---|---|
Control | 100 nM Dex | 1 μM Dex | ||
GAPDH | 18,911 | 20,491 | 19,537 | |
β-Actin | 18,544 | 19,673 | 18,732 | |
MT-1A | 3,883 | 6,710 | 8,508 | |
IκBα | 1,726 | 3,206 | 3,109 | |
IL-8 | 527 | ND | ND | |
DUSP1 | MKP-1, CL-100, Erp | 3,387 | 6,436 | 5,951 |
DUSP2 | PAC-1 | 343 | 903 | 879 |
DUSP4 | MKP-2, hVH2 | 230 | 389 | 339 |
DUSP5 | hVH3 | 324 | ND | ND |
DUSP10 | MKP-5 | 288 | 305 | 356 |
DUSP11 | PIR1 | 1,960 | 1,576 | 1,508 |
Wip1 | 685 | 573 | 506 |
HeLa-TO cells were treated for 2 h with vehicle (methanol) (control) or with 100 nM or 1 μM dexamethasone (Dex). Total RNA was prepared and analyzed using Affymetrix U95Av2 arrays as described in Materials and Methods. Raw data sets from the chip reader were normalized against one another using the mean expression level of all detected transcripts under each condition. Correction factors applied to the 100 nM and 1,000 nM dexamethasone data sets were 1.156 and 0.99, respectively. Normalization using the GAPDH or β-actin signals gave almost identical results. Normalization using internal control poly(A) mRNAs (added at the cRNA synthesis step) suggested slightly stronger up-regulation of MKP-1 gene expression by 100 and 1,000 nM dexamethasone (2.4- and 2.6-fold rather than 1.7-and 1.5-fold as shown above). An arbitrary cutoff of 200 expression units was employed, and genes expressed below this level were considered not detected (ND).